Biogen Idec abandoning Weston, plots move to Kendall Sq

Just a year after moving its headquarters to a gleaming new campus in Weston, MA, new Biogen Idec CEO George Scangos is bringing the whole crew--530 staffers--back to Kendall Square in Cambridge. The Boston Globe reports that Biogen will build two new buildings as it once again consolidates its HQ staff with R&D, an objective that Scangos has clearly been yearning for ever since he took the reins.

"We want to be the very best at what we do,'' Scangos told the Globe. "We have a lot on our plate, and execution will be absolutely critical. Being geographically separated, there's a barrier.''

The news will come as no surprise to anyone working at the Big Biotech. Scangos had taken up spare office space in Kendall Square, anxious to stay close to research and development. As CEO at Exelixis, Scangos had initiated a broad array of drug studies. And he's clearly excited about Biogen's pipeline.

Biogen has blueprinted 500,000 square feet of space in the two new buildings. "We're not moving because we don't like Weston,'' he said. "Weston is a gorgeous place. [But] this...is a much more efficient way to run the business."

- here's the report in the Boston Globe

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.